The cell culture industry, which began in the late 1980s from the utilization of recombinant DNA technology and cell hybridization, is now a significant foundation of the biopharmaceutical annual market of $30 Billion. In 2000-2003, regulators in North America and Europe approved a total of 64 biopharmaceuticals for human use. The approved drugs included hormones, blood factors, thrombolytics, vaccines, interferons, monoclonal antibodies (MAb), and therapeutic enzymes. Many of these were produced in mammalian cell culture systems. An estimated 50 new chemical entities were approved in the same period and over a quarter of all new drug approvals were biopharmaceuticals. All of …
Комментариев нет:
Отправить комментарий